1.18
+0.01(+0.85%)
Currency In USD
| Previous Close | 1.17 |
| Open | 1.17 |
| Day High | 1.22 |
| Day Low | 1.17 |
| 52-Week High | 1.69 |
| 52-Week Low | 0.75 |
| Volume | 213,376 |
| Average Volume | 379,126 |
| Market Cap | 43.24M |
| PE | -3.11 |
| EPS | -0.38 |
| Moving Average 50 Days | 1.16 |
| Moving Average 200 Days | 1.17 |
| Change | 0.01 |
If you invested $1000 in RenovoRx, Inc. (RNXT) since IPO date, it would be worth $162.53 as of September 28, 2025 at a share price of $1.18. Whereas If you bought $1000 worth of RenovoRx, Inc. (RNXT) shares 3 years ago, it would be worth $590 as of September 28, 2025 at a share price of $1.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
GlobeNewswire Inc.
Sep 25, 2025 12:30 PM GMT
First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer Center Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of Vermont Cancer Center as Participating Clinical Si
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
GlobeNewswire Inc.
Sep 11, 2025 12:30 PM GMT
MOUNTAIN VIEW, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleare
RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
GlobeNewswire Inc.
Aug 06, 2025 12:30 PM GMT
RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are currently purchasing and have made repeat orders of Ren